SOUTH SAN FRANCISCO, Calif. / Oct 15, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 after the close of market on Tuesday, November 4, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on... Read More

Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif. / Sep 28, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the PAM50 molecular signature predicts which patients with recurrent prostate cancer... Read More

Findings are among nine Decipher-focused abstracts being presented at annual conference SOUTH SAN FRANCISCO, Calif. / Sep 24, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a molecular signature to predict hormone therapy benefit in men with recurrent prostate cancer will be presented at ASTRO 2025, the annual meeting... Read More

Studies leverage company’s Afirma Genomic Resource for Intelligent Discovery (GRID), world’s largest molecular database for thyroid nodules SOUTH SAN FRANCISCO, Calif. / Sep 09, 2025 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 12 Afirma-related abstracts will be presented at the 2025 American Thyroid Association Annual Meeting, taking place September 10-14 at... Read More

SOUTH SAN FRANCISCO, Calif. / Aug 29, 2025 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced today that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 p.m. Eastern Time. A live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at... Read More

Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial SOUTH SAN FRANCISCO, Calif. / Aug 27, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic Classifier predicts which patients with metastatic cancer are likely to benefit from treatment... Read More

SOUTH SAN FRANCISCO, Calif. / Aug 26, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has met its targeted enrollment for the NIGHTINGALE trial, which aims to evaluate the clinical utility of its Percepta Nasal Swab test. The milestone marks an important step in Veracyte’s goal of making the novel molecular test widely available and helping clinicians to better... Read More

Grew total revenue to $130.2 million and testing revenue to $122.3 million, representing increases of 14% year-over-year Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. / Aug 06, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025. “Testing growth continues to exceed our... Read More

SOUTH SAN FRANCISCO, Calif. / Jul 17, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter of 2025 after the close of market on Wednesday, August 6, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on... Read More

SOUTH SAN FRANCISCO, Calif. / Jul 08, 2025 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that three Afirma-related abstracts will be presented at ENDO 2025, the annual meeting of the Endocrine Society, taking place July 12-15 in San Francisco. The findings are derived from Veracyte’s Afirma GRID (Genomic Resource for Intelligent Discovery) database and research tool... Read More

SOUTH SAN FRANCISCO, Calif. / May 28, 2025 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that eight abstracts featuring data derived from testing with its Decipher Prostate and Decipher Bladder genomic classifiers will be presented at ASCO, the annual meeting of the American Society of Clinical Oncology, being held May 30-June 3 in Chicago. Key findings shed new light... Read More

SOUTH SAN FRANCISCO, Calif. / May 20, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. William Blair 45 th Annual Growth Stock Conference – Chicago, IL Presentation on June 3 rd at 5:40 p.m. Eastern Time Jefferies Global Healthcare Conference – New York, NY Presentation on June 4 th at 2:00 p.m. Eastern Time... Read More

Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. / May 07, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 25, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic Classifier for use in patients whose prostate cancer has spread beyond the primary tumor. The Decipher Prostate test, already widely used for patients with localized disease, is now the only gene expression test available and... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 22, 2025 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that at least 18 abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2025, the annual meeting of the American Urological Association, taking place April 26-29 in Las Vegas. Study findings to be presented include new data... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 21, 2025 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from its market-leading Decipher Prostate Genomic Classifier are available in a new specialized database that the National Cancer Institute’s (NCI’s) Surveillance, Epidemiology, and End Results (SEER) Program just released . This database will enable eligible researchers... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 16, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter of 2025 after the close of market on Wednesday, May 7, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the... Read More

Findings from TOMBOLA Trial Were Presented at EAU25 SOUTH SAN FRANCISCO, Calif. / Mar 25, 2025 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its whole-genome sequencing (WGS)-based platform for minimal residual disease (MRD) testing detected cancer in patients treated for muscle-invasive bladder cancer (MIBC) with more accuracy than ddPCR-based... Read More

SOUTH SAN FRANCISCO, Calif. / Mar 19, 2025 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that multiple abstracts will be presented at the 40 th Annual European Association of Urology Congress (EAU25) demonstrating the clinical performance and utility of its Decipher tests in prostate and bladder cancer. Additionally, independent performance data supporting the... Read More

Grew fourth quarter total revenue to $118.6 million, an increase of 21% Grew fourth quarter testing revenue to $112.2 million, an increase of 24% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. / Feb 24, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. “I’m incredibly proud of what our team... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 19, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 46 th Annual Institutional Investors Conference – Orlando, FL Presentation on March 5 th at 9:50 a.m. Eastern Time Leerink Partners Global Healthcare Conference – Miami, FL Fireside Chat on March 11 th at 8:40... Read More

Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology SOUTH SAN FRANCISCO, Calif. / Feb 14, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical utility... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 11, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 17 Decipher-focused abstracts will be presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU). The findings demonstrate the market leadership of its Decipher tests in better informing treatment decisions for patients with prostate and bladder cancers, compared to... Read More

Findings Further Expand Company’s Extensive Clinical Evidence In Urologic Cancers SOUTH SAN FRANCISCO, Calif. / Feb 05, 2025 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data that reinforce the ability of its Decipher Bladder Genomic Subtyping Classifier to help improve staging for patients with bladder cancer, based on their tumors’ molecular subtype. The... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 04, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2024 after the close of market on Monday, February 24, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m.... Read More

SOUTH SAN FRANCISCO, Calif. / Dec 05, 2024 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the only gene expression test to be included in version 1 of the 2025 NCCN * Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) as part of the updated “Advanced Tools” table located in the Principles of... Read More

Grew total revenue to $115.9 million, an increase of 29% Grew testing revenue to $109.5 million, an increase of 34% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. / Nov 06, 2024 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2024. "The strong momentum across our testing business continued during the third quarter as we... Read More

SOUTH SAN FRANCISCO, Calif. / Oct 30, 2024 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. UBS Healthcare Conference – Rancho Palos Verdes, CA Fireside Chat on November 12 th at 2:45 p.m. Eastern Time Guggenheim Inaugural Healthcare Innovation Conference – Boston, MA Fireside Chat on November 13 th at 3:00 p.m.... Read More

SOUTH SAN FRANCISCO, Calif. / Oct 16, 2024 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024 after the close of market on Wednesday, November 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on... Read More

Findings are from the prospective, multicenter VANDAAM trial SOUTH SAN FRANCISCO, Calif. / Oct 02, 2024 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new data from the multicenter, prospective VANDAAM trial show that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among African American men with early-stage disease. The findings... Read More

Findings are from ancillary study of phase 3 STAMPEDE trial Data support company’s plan to expand Decipher Prostate test to patients with metastatic disease SOUTH SAN FRANCISCO, Calif. / Sep 15, 2024 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data from a phase 3 trial of the multi-center, randomized STAMPEDE clinical trial show that its Decipher Prostate... Read More

SOUTH SAN FRANCISCO, Calif. / Sep 04, 2024 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. “We are thrilled to welcome Brent and Tom to our board,” said Marc Stapley,... Read More

SOUTH SAN FRANCISCO, Calif. / Aug 26, 2024 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 22 nd Annual Global Healthcare Conference on Thursday, September 5, at 2:35 p.m. Eastern Time. A live audio webcast of the company’s presentation will be available by... Read More

Award marks company’s 11 th consecutive year of receiving this honor SOUTH SAN FRANCISCO, Calif. / Aug 26, 2024 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it has been named a Bay Area Top Workplace by the San Francisco Chronicle . The award marks the 11 th consecutive year that Veracyte has received this honor. The Bay Area Top Workplace award winners are... Read More

Grew total revenue to $114.4 million, an increase of 27% Grew testing revenue by 31% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. / Aug 06, 2024 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2024. “Our exceptional second quarter results are a testament to the strength and robustness of Decipher and Afirma,” said Marc... Read More

SOUTH SAN FRANCISCO, Calif. / Jul 17, 2024 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2024 after the close of market on Tuesday, August 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be... Read More

Findings presented at the ENDO 2024 conference SOUTH SAN FRANCISCO, Calif. / Jun 03, 2024 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new research findings suggesting the potential of novel molecular signatures to identify patients with thyroid nodules or cancer who have aggressive disease. The findings, which could potentially help clinicians further individualize... Read More

SOUTH SAN FRANCISCO, Calif. / May 22, 2024 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from three studies will demonstrate the power of the Afirma GRID (Genomic Resource for Intelligent Discovery) tool to help unlock new molecular insights into thyroid tumors, which may ultimately help to further personalize treatment of the disease. The findings will be... Read More

SOUTH SAN FRANCISCO, Calif. / May 15, 2024 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, today announced it will participate in the following investor conferences. Leerink Partners 2024 Healthcare Crossroads Conference – Austin, TX Fireside Chat on May 29 th at 12:20 p.m. Eastern Time William Blair 44 th Annual Growth Stock Conference – Chicago, IL Presentation on June 4 th at 5:40... Read More

Grew total revenue to $96.8 million, an increase of 17% Grew testing revenue by 25% Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. / May 07, 2024 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024. “We had a strong start to 2024, driven by robust growth from our market-leading Decipher Prostate and Afirma tests. We... Read More

Large number of abstracts also showcases power of the Veracyte Diagnostics Platform SOUTH SAN FRANCISCO, Calif. / May 06, 2024 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 22, 2024 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, May 7, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 22, 2024 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance (AS) for prostate cancer, the Decipher Prostate Genomic Classifier is prognostic for identifying those whose disease is likely to progress. The findings make the Decipher... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 16, 2024 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2024, the annual meeting of the American Urological Association, taking place May 3-6 in San Antonio. Studies to be presented include those that evaluate the... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 27, 2024 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in the 2024 NCCN * Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) as a prognostic tool for the risk stratification of patients with localized... Read More

Grew Fourth Quarter Revenue to $98.2 million Increased 2023 Total Revenue 22% to $361.1 million Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. / Feb 22, 2024 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023. “We closed 2023 with another quarter of excellent results, driven by our Afirma and Decipher... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 21, 2024 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and John Leite, Ph.D., chief commercial officer, CLIA, will present at the Raymond James 45 th Annual Institutional Investors Conference on Monday, March 4, 2024, at 9:50 a.m. Eastern Time. A live audio webcast of the company’s presentation will be available by visiting... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 08, 2024 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2023 after the close of market on Thursday, February 22, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The... Read More

Extends Veracyte’s novel diagnostics platform with whole-genome minimal residual disease capabilities Expands company’s presence across the cancer care continuum SOUTH SAN FRANCISCO, Calif. / Feb 06, 2024 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has completed its acquisition of C2i Genomics, Inc., adding whole-genome minimal residual disease (MRD) capabilities... Read More

Grew full-year revenue to between $358 million and $359 million, an increase of 21% Acquisition broadens Veracyte’s presence across the cancer care continuum SOUTH SAN FRANCISCO, Calif. / Jan 08, 2024 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2023. The company also... Read More

SOUTH SAN FRANCISCO, Calif. / Dec 12, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will present at the 42 nd annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 1:30 p.m. Pacific Time. A live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at... Read More

SOUTH SAN FRANCISCO, Calif. / Dec 01, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced that new data presented today at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023) highlight clinical observations and translational research conducted by users of the company’s Decipher Prostate Genomic Classifier. These independent, real-world studies provide further evidence supporting the clinical... Read More

Non-invasive genomic test is designed to help physicians guide next steps for current and former smokers with lung nodules SOUTH SAN FRANCISCO, Calif. / Nov 29, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced that clinical validation data published in the journal CHEST show that the company’s Percepta Nasal Swab test determines lung cancer risk, with high accuracy, among people who currently smoke or have... Read More

SOUTH SAN FRANCISCO, Calif. / Nov 22, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment. Collectively,... Read More

Grew Total Revenue to $90.1 million, an Increase of 19% Grew Testing Revenue by 27% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. / Nov 07, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2023. “I am pleased to share we delivered another quarter of strong revenue growth, fueled by continued demand for our Decipher... Read More

Agreement is part of Veracyte’s multi-platform strategy for its decentralized IVD tests outside of the U.S. SOUTH SAN FRANCISCO, Calif. / Nov 07, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) today announced that it has entered into a multi-year agreement with Illumina, Inc. (Nasdaq: ILMN) to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina’s... Read More

SOUTH SAN FRANCISCO, Calif. / Nov 02, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced today that Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Stephens Annual Investment Conference on Wednesday, November 15, at 3:00 p.m. Eastern Time. A live audio webcast of the company’s presentations will be available by visiting Veracyte’s website at... Read More

Two abstracts show the potential for using Veracyte’s tools to characterize the tumor microenvironment SOUTH SAN FRANCISCO, Calif. / Oct 27, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced that two poster presentations taking place at SITC 2023, the annual meeting of the Society for Immunotherapy of Cancer, in San Diego from November 3-5 will demonstrate the potential for using the company’s novel tools... Read More

SOUTH SAN FRANCISCO, Calif. / Oct 17, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the third quarter of 2023 after the close of market on Tuesday, November 7, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be... Read More

Two studies highlight the value of adding Envisia results to standard-of-care procedures for identifying patients at increased risk of progressive disease SOUTH SAN FRANCISCO, Calif. / Oct 12, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) today announced that new data presented at the American College of Chest Physicians (CHEST) Annual Meeting 2023 demonstrate the clinical utility of the company’s Envisia Genomic... Read More

Findings presented at the 2023 ASTRO Annual Meeting expand substantial body of evidence demonstrating Decipher Prostate test’s ability to help inform prostate cancer treatment decisions. Additional study suggests level of evidence supporting commercially available genomic classifiers should drive utilization. SOUTH SAN FRANCISCO, Calif. / Oct 04, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) today announced that new... Read More

Company also introduces research-use-only Afirma Genomic Resource for Intelligent Discovery (GRID) platform for additional insights into thyroid nodules and cancer SOUTH SAN FRANCISCO, Calif. / Sep 28, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) today announced that new data presented at the 2023 American Thyroid Association (ATA) Annual Meeting demonstrate the type of novel molecular insights for thyroid nodules... Read More

SOUTH SAN FRANCISCO, Calif. / Sep 28, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced that six abstracts highlighting new data from studies evaluating the company’s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2023 taking place October 1-4 in San Diego. The accepted abstracts... Read More

SOUTH SAN FRANCISCO, Calif. / Sep 27, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte’s global team of research... Read More

Three abstracts demonstrate new insights that can be derived from whole-transcriptome-based thyroid cancer molecular profiles SOUTH SAN FRANCISCO, Calif. / Sep 21, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced that three posters showcasing new data from the company’s Afirma Genomic Sequencing Classifier (GSC) will be presented at the 2023 American Thyroid Association (ATA) Annual Meeting being held in... Read More

SOUTH SAN FRANCISCO, Calif. / Sep 07, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced that Marie-Claire Taine, Ph.D., will join Veracyte as general manager of the company’s in vitro diagnostics (IVD) Business Unit, based in Marseille, France. She will lead the global expansion of Veracyte’s tests and will also serve as site lead for the company’s Marseille operations. Dr. Taine is a highly credentialed... Read More

Partnership will leverage Gustave Roussy’s tumor samples and Veracyte’s Biopharma Atlas multi-omic database and machine learning capabilities SOUTH SAN FRANCISCO, Calif. & PARIS / Sep 06, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced today that they have entered into a collaboration to bring together their respective... Read More

SOUTH SAN FRANCISCO, Calif. / Aug 29, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 21 st Annual Global Healthcare Conference on Tuesday, September 12, at 4:15 p.m. Eastern Time. A live audio webcast of the company’s presentations will be available by... Read More

New data are from a retrospective analysis of the Phase 2 STREAM trial SOUTH SAN FRANCISCO, Calif. / Aug 22, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced that new data published in JCO Precision Oncology suggest that gene expression signatures derived from the company’s Decipher Genomics Resource for Intelligent Discovery (GRID) database may help advance understanding of the genomic drivers impacting... Read More

Awards mark Veracyte’s 10 th consecutive honor in the Bay Area and inaugural recognition in San Diego SOUTH SAN FRANCISCO, Calif. / Aug 15, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced that its South San Francisco and San Diego offices have been named top workplaces. Veracyte’s South San Francisco location has been awarded a Top Bay Area Workplaces 2023 honor by the San Francisco Chronicle , in partnership... Read More

Grew Total Revenue to $90.3 million, an Increase of 24% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. / Aug 08, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2023. “We delivered outstanding second quarter results, with revenue and test volume that exceeded our expectations. We also generated a record $17 million in... Read More

Clinical utility study findings based on analysis of the National Cancer Institute’s SEER database SOUTH SAN FRANCISCO, Calif. / Aug 01, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced the publication of a large, real-world study reinforcing the Decipher Prostate Genomic Classifier’s ability to guide personalized treatment approaches for men with prostate cancer. The study utilized data from the first linkage... Read More

SOUTH SAN FRANCISCO, Calif. / Jul 19, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2023 after the close of market on Tuesday, August 8, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be... Read More

Findings presented at ENDO 2023 also confirm analytical validity of company’s TERT promoter gene mutation testing for thyroid nodule patients SOUTH SAN FRANCISCO, Calif. / Jun 20, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced that new data presented at ENDO 2023, the annual meeting of The Endocrine Society, suggest the company’s Afirma molecular testing and whole-transcriptome capabilities can provide novel... Read More

A scientific-data oral presentation, two posters and a symposium presentation will highlight the clinical and research advantages of the company’s Afirma molecular test and capabilities SOUTH SAN FRANCISCO, Calif. / Jun 12, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts highlighting new data on the company’s Afirma test and capabilities will be presented at ENDO 2023, the annual... Read More

SOUTH SAN FRANCISCO, Calif. / May 25, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced that new data to be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrate the ability of the company’s Decipher Genomics Resource for Intelligent Discovery (GRID) database to enable novel molecular insights into prostate cancer. The findings, from three separate studies, may ultimately... Read More

SOUTH SAN FRANCISCO, Calif. / May 24, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer. The findings were presented at ATS 2023, the annual meeting of the American Thoracic Society, which is being held May 21-24 in Washington, D.C. Findings... Read More

SOUTH SAN FRANCISCO, Calif. / May 23, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences: William Blair 43 rd Annual Growth Stock Conference – Chicago, IL Presentation on June 6 th at 9:40 a.m. Eastern Time Goldman Sachs 44 th Annual Global Healthcare Conference –... Read More

Findings from prospective, population-based study presented at ESMO Breast Cancer Congress 2023 SOUTH SAN FRANCISCO, Calif. / May 12, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for patients with early-stage breast cancer, including significantly reducing the use of chemotherapy among those with clinically high-risk... Read More

Grew Total Revenue to $82.4 million, an Increase of 22% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. / May 04, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2023. “We had an excellent first quarter, as many areas of our business greatly exceeded our expectations. Not only did we deliver strong Afirma and Decipher... Read More

Findings reinforce value of Veracyte’s expanded Afirma offering, which now includes TERT gene mutation testing SOUTH SAN FRANCISCO / May 04, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced findings from a large-scale, systematic literature review showing that TERT promoter gene mutations in thyroid nodules deemed indeterminate by cytopathology are rare, but have a high risk of malignancy and, in certain... Read More

SOUTH SAN FRANCISCO, Calif. / May 03, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced that data published in the journal Cancer show the ability of a novel gene expression signature to classify prostate cancer into distinct molecular subtypes that may inform which tumors are more likely to respond to different treatments. The findings suggest that the novel biomarker, derived largely using Veracyte’s Decipher... Read More

SOUTH SAN FRANCISCO, Calif. / May 03, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced that it released its inaugural Environmental, Social and Governance (ESG) Report . The 2023 ESG Report sets the foundation for Veracyte’s ESG performance and outlines the company’s ambitions to build upon its progress in the years ahead. “As our company has grown, we have embraced our responsibility to advance our ESG... Read More

Findings represent first validation of any gene expression biomarker for intermediate-risk patients using data from a randomized phase 3 clinical trial SOUTH SAN FRANCISCO, Calif. / May 02, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, “The Red Journal”) validate the clinical utility of the company’s Decipher... Read More

SOUTH SAN FRANCISCO, Calif. / May 01, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts focused on the company’s genomic tests for interstitial lung disease (Envisia Genomic Classifier) and lung cancer (Percepta Nasal Swab) will be presented at the American Thoracic Society (ATS) 2023 International Conference. The meeting will take place May 19-24 in Washington, D.C. “We look forward... Read More

Data from studies encompassing over 100,000 prostate cancer patients presented at American Urology Association (AUA) 2023 Annual Meeting SOUTH SAN FRANCISCO, Calif. / Apr 29, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced that new data presented at the American Urological Association (AUA) 2023 Annual Meeting validate the real-world performance and clinical utility of the company’s Decipher Prostate Genomic... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 27, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced that five abstracts providing new molecular insights into prostate and other cancers will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago and online June 2-6. Three of the accepted abstracts leverage Veracyte’s Decipher GRID (Genomic Resource for Intelligent... Read More

Findings published in European Urology Oncology suggest genomic classifier scores are highly correlated with PSMA PET upstaging of prostate cancer in those with high-risk and very high-risk disease SOUTH SAN FRANCISCO, Calif. / Apr 17, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced that new data published in European Urology Oncology suggest the Decipher Prostate Genomic Classifier could help identify... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 13, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2023 after the close of market on Thursday, May 4, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be... Read More

Accepted abstracts include three summarizing findings from separate, large-scale, real-world studies evaluating clinical utility of Decipher Prostate Genomic Classifier SOUTH SAN FRANCISCO, Calif. / Apr 12, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced today that seven abstracts highlighting new data from studies of the company’s Decipher urologic cancer tests will be presented at the American Urological... Read More

SOUTH SAN FRANCISCO, Calif. / Mar 15, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.... Read More

SOUTH SAN FRANCISCO, Calif. / Mar 11, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) outlined the company’s cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank (SVB). As of December 31, 2022, the company had $178.9 million in cash, cash equivalents and short-term investments. The majority of these assets are not restricted by the Federal Deposit Insurance... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 27, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences. Cowen’s 43rd Annual Health Care Conference – Boston, MA Presentation on March 7 th at 9:50 a.m. Eastern Time KeyBanc Virtual Life Sciences & MedTech Investor Forum Fireside... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 22, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2022. “We had an outstanding fourth quarter, driving record revenue and operating cash flows, achieving the best quarter ever for both our Decipher prostate and Afirma thyroid tests,” said Marc Stapley, Veracyte’s chief executive officer.... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 15, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) today announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, “The Red Journal”) demonstrate that the company’s Decipher Prostate Genomic Classifier can improve risk stratification among men with clinically high-risk prostate cancer. The data, from a pre-specified analysis of three... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 13, 2023 / Business Wire / Veracyte, Inc . (Nasdaq: VCYT) announced new data being presented this week at the 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium which demonstrate that a gene expression signature derived from the company’s proprietary Decipher Genomics Resource for Intelligent Discovery (GRID) database may help physicians further personalize... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 06, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2022 after the close of market on Wednesday, February 22, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The... Read More

Findings published in Frontiers in Endocrinology were derived from analyses of Veracyte’s comprehensive thyroid nodule database of whole transcriptome sequencing SOUTH SAN FRANCISCO, Calif. / Feb 01, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) today announced that data published in Frontiers in Endocrinology provide new insights into the frequency and risk of malignancy (ROM) associated with thyroid stimulating... Read More